Dan

PITTSBURGH, PA, March 1, 2023 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced Robert Keefe, Ph.D., Chief Development Officer of BlueSphere Bio, will present an overview of the Company’s anticipated first in human

PITTSBURGH, PA, February 6, 2023 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced Keir Loiacono, Chief Executive Officer of BlueSphere Bio, will present a corporate overview at the 2023 BIO CEO & Investor

Dr. Bahceci brings more than two decades of combined clinical and drug development experience PITTSBURGH, PA, January 30, 2023 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced the appointment of Erkut Bahceci, M.D.,

PITTSBURGH, Nov. 10, 2022 (GLOBE NEWSWIRE) — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced the presentation of data supporting the potential of its first and lead product candidate, BSB-1001, at the 37th Society for

PITTSBURGH, PA, November 03, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced that Robert Keefe, Ph.D., Chief Development Officer of BlueSphere Bio, will present data in a poster at the 37th Society